PRINCETON, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Company (NASDAQ: IART), a leading global medical technology company, today issued its latest Environmental, Social and Governance (ESG) report. The report highlights the company’s 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago.
“Innovating treatment pathways to advance patient outcomes and set new standards of care is work that matters to our Integra colleagues around the world and is what drives us each and every day,” said Jan De Witte, president and chief executive officer, Integra LifeSciences. “We are pleased with the advances we have made to meet our ESG commitments and ambitions as we play our part to create healthier people, a healthier workplace and a healthier world.”
Integra’s ESG report includes the past year’s highlights in key areas:
Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index.
Read the full report here.
About Integra
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit investor.integralife.com.
Contacts:
Investors:
Chris Ward
(609) 936-2322
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Laurene Isip
(609) 208-8121
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$15.83 |
Daily Change: | 0.08 0.51 |
Daily Volume: | 416,470 |
Market Cap: | US$1.220B |
March 13, 2025 February 25, 2025 November 13, 2024 November 04, 2024 November 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load